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INTRODUCTION
The standard management of advanced epithelial ovarian 
cancer (EOC) is staging laparotomy with resection of gross 
disease, followed by first-line adjuvant chemotherapy 
composed of intravenous (IV) taxane and a platinum-based 
regimen. Even though cytoreductive surgery and adjuvant 
IV chemotherapy have achieved a considerably high clinical 
complete response rate (up to 50%), many responding 
patients suffer from abdominopelvic failures (APF) with a 
median progression-free survival of 15.5-22 months [1-3]. Un-
fortunately, patients with macroscopic residual disease or APF 
after initial treatment usually cannot maintain disease-free 
status in spite of further chemotherapy. Therefore, effective 
adjuvant locoregional treatment to consolidate or maintain 
the response achieved by maximal debulking surgery and 
adjuvant IV chemotherapy is required for patients at a high 
risk for APF [4].
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Objective: To analyze patterns of abdominopelvic failures and to define subgroups for the use of adjuvant radiotherapy in the 
International Federation of Gynecology and Obstetrics (FIGO) stage III epithelial ovarian cancer (EOC). 
Methods: We reviewed 149 patients treated with debulking surgery followed by intravenous taxane and platinum 
chemotherapy between 1999 and 2008. Patient characteristics, patterns of failure, abdominopelvic failure APF-free survival 
(APFFS) and overall survival (OS) were analyzed. 
Results: The median age of the patients was 51 years. Thirty-two patients (21.5%) were found to have residuum >2 cm after 
surgery. The median pretreatment CA-125 was 604 and 54.4% of patients had a decline in CA-125 ≥90% between pretreatment 
and at postoperative 1 month. With a median follow-up of 50 months, 79 patients (53.0%) experienced abdominopelvic failure 
(APF). The 5-year APF-free survival rate was 41.1%. Lymph node metastasis, size of residual disease, and decline in CA-125 were 
found to be significant prognostic factors for APF upon multivariate analysis. The group of patients in whom abdominopelvic 
irradiation was indicated as definitive postoperative treatment comprised 55% of the overall patient population and their 5-year 
survival rate was 68%.
Conclusion: The stratification was suggested to predict APF based on lymph node metastasis, size of residual tumor, and 
decline in CA-125. Adjuvant radiotherapy covering the whole abdominopelvis using the intensity modulation technique may be 
considered to reduce APF in FIGO stage III EOC patients with intermediate risk. 
Keywords: Abdominopelvic recurrences, Adjuvant radiotherapy , Epithelial ovarian cancer, Patterns of failure
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Whole abdominal radiotherapy (WART) has also been used 
as consolidation treatment after cytoreductive surgery and 
adjuvant chemotherapy, but its clinical significance has been 
controversial [5]. Even though many studies have suggested a 
possible benefit of WART for patients with tumors in complete 
pathologic remission or with minimal residual disease, the 
therapy has some limitations that prevent it from being 
adopted as one of the standard treatment modalities for 
advanced stage EOC. The purpose of this study was to analyze 
patterns of APF in International Federation of Gynecology and 
Obstetrics (FIGO) stage III EOC patients treated with cytore-
ductive surgery and intravenous adjuvant taxane-platinum 
chemotherapy and to define subgroups for which WART will 
be beneficial as a consolidation therapy. 
MATERIALS AND METHODS
Between 1999 and 2008, a total of 572 women were patho-
logically diagnosed with epithelial ovarian malignancy at 
Severance Hospital, Yonsei University College of Medicine, 
Seoul, Korea. Among them, 325 patients had proven FIGO 
stage III EOC, and 176 of them were excluded because of 
intraperitoneal taxane and platinum-based chemotherapy 
(n=79), neoadjuvant chemotherapy before surgery (n=21), 
double primary malignancy (n=15), postoperative adjuvant 
radiotherapy (n=14), loss to follow-up (n=14), or second-look 
operation (n=1). Therefore, 149 patients were eligible for this 
analysis. 
Patients who were suspected to have ovarian malignancy 
underwent a thorough history and full physical and pelvic 
examination. Complete blood count, chemistries, urinalysis 
and chest X-rays were also routinely evaluated. Pelvic 
ultrasound was initially used to evaluate a suspicious adnexal 
mass. To identify tumor extent, abdominopelvic computed 
tomography (CT), magnetic resonance imaging or positron 
emission tomography (PET), or PET/CT were analyzed. Patients 
with clinical indication were further examined with mam-
mography, upper gastrointestinal endoscopy, or colonoscopy. 
Tumor markers were evaluated for differential diagnosis 
between non-epithelial and epithelial tumors and for a 
definitive diagnosis of an epithelial tumor. The difference in 
CA-125 level before treatment and postoperative 1 month 
was calculated as follows: CA-125 decline (%)=(pretreatment 
value-postoperative 1 month value)/pretreatment value×
100. We defined the optimal cut-off value for survival as that 
which gave the greater degree of sensitivity and specificity to 
dichotomize patients in univariate analysis, even though there 
were several cut-off values that impacted survival. 
All patients underwent staging laparotomy which included 
cytologic examination of ascites or peritoneal washings, 
intact tumor removal, thorough inspection of the abdomen 
and pelvis, total abdominal hysterectomy, bilateral salpingo-
oophorectomy, partial or total omentectomy, pelvic node 
dissection, para-aortic lymph node sampling, and targeted 
biopsies of suspected peritoneal metastases. All surgical speci-
mens were examined using the same pathologic protocol. 
Surgical information included the maximum size of largest 
residual tumor at the surgery. The histological classification 
and grade of ovarian malignancy were based on the World 
Health Organization classifications. The FIGO classification 
system was used to determine pathological staging of the 
tumors. 
For all patients, chemotherapy was started within approxi-
mately 2 weeks after surgery. The regimen was a combination 
of one taxane and one platinum derivative. Taxane derivatives 
included paclitaxel (175 mg/m2) and docetaxel (75 mg/m2), 
and the platinum derivative was either cisplatin (70 mg/m2) 
or carboplatin (target area under the curve [AUC] of 5). After 
completion of chemotherapy, patients underwent physical 
examination, CA-125, and CT or PET/CT scan of the abdomen 
and pelvis for clinical restaging. Only patients with no clinical, 
radiographic, or biochemical (CA-125<35 U/mL) evidence of 
disease were recommended to periodical routine check-up; 
those with residual or progressive disease after chemotherapy 
underwent second line chemotherapy at the discretion of 
their physician. 
We classified patterns of treatment failure into APF and dis-
tant metastasis. APF included intraperitoneal, retroperitoneal 
space and the pelvic cavity. Distant metastasis was defined as 
recurrence in solid organs such as bones, lungs, liver, or brain. 
APF-free survival (APFFS) and overall actuarial survival (OS) 
rates were calculated using the Kaplan-Meier method, and 
differences were compared using the log-rank test. Univariate 
analysis was used to define the prognostic factors influenc-
ing APF and OS. The relative importance of the covariates 
in determining prognostic factors was also assessed by a 
multivariate Cox proportional hazards model. A p-value ≤0.05 
was considered significant. 
After completion of chemotherapy, patients were followed 
at the Women’s Cancer Clinic at Hospital every three months 
during the first two years, every six months during the next 
three years, and then every year afterwards. Patients were 
examined at each visit, utilizing a complete history taking/
physical examination. The follow-up evaluations included 
CA-125, CT scans of the chest and abdomen, and [18F]flude-
oxyglucose (FDG) PET/CT. Generally, CA-125 and abdomen 
CT were performed every 6 months during first 3 years and 
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annually during the next 2 years. FDG PET/CT was performed 
after last cycle of first-line chemotherapy, and then annually. 
Recurrence was treated by salvage chemotherapy, surgery, or 
radiotherapy.
RESULTS
Patient characteristics and clinical profiles are listed in Table 1. 
The ages of the patients ranged from 18 to 77 years (median, 
51 years). Serous adenocarcinoma accounted for four fifths of 
all tumors, and 73 tumors (49.0%) were poorly differentiated. 
Thirty two patients (21.5%) had larger than 2 cm sized gross 
residual disease after cytoreductive surgery, and malignant 
cells were found in peritoneal washing cytology in 95 patients 
(63.8%). One hundred and forty patients (94.0%) received sys-
tematic lymphadenectomy. The median number of dissected 
nodes was 24 (range, 2 to 70). The incidence of pathologic 
node positivity was 60.4% (n=90), and the median number of 
resected metastatic nodes was 3 (range, 1 to 45), which were 
found in the pelvis (n=48, 32.2%), para-aortic lymph nodes 
(n=14, 9.4%), or both (n=28, 18.8%). The median pretreatment 
CA-125 level was 604 (range, 12.5 to 12,000). CA-125 level 
declined by more than 90% in 81 patients after surgery. 
Chemotherapeutic regimens were comprised as follows: 
paclitaxel and carboplatin in 94 patients (63.1%), paclitaxel 
and cisplatin in 22 patients (14.8%), docetaxel and carboplatin 
in 20 patients (13.4%), docetaxel+cisplatin in 8 patients (5.4%), 
and paclitaxel+carboplatin/cisplatin in 5 patients (3.4%). Most 
patients received at least six cycles. However, 15 patients 
did not finish six cycles of adjuvant chemotherapy due to 
chemotherapy-related toxicity.
During the median follow-up duration of 50 months (range, 
0 to 136.5 months), 83 patients (55.7%) experienced treat-
ment failure. Of these 83 patients, 70 patients (47.0%) had APF 
only, 9 patients (6.0%) had APF with distant metastasis, and 4 
patients (2.7%) had distant metastasis only as the first site of 
failure. Survival analysis showed that the 5-year APFFS and OS 
were 41.1% and 56.7%, respectively. The sites of distant me-
tastasis were the liver (n=6, 4.0%), supraclavicular-mediastinal 
lymph node (n=4, 2.7%), lung (n=3, 2.0%), and brain (n=2, 
1.3%).
According to univariate analysis, the significant prognostic 
indicators for APFFS were age, grade, peritoneal washing 
cytology, peritoneal metastasis, lymph node involvement, 
residual disease, and percentage of CA-125 decline (Table 2). 
They were also significantly prognostic for OS. Cox regression 
analysis identified lymph node involvement, residual disease 
and percentage of CA-125 decline as independent prognostic 
factors for APFFS. For OS, age, grade, peritoneal washing cytol-
ogy, and percentage of CA-125 decline retained significance 
in multivariate analysis (Table 3).
We divided the patients into subgroups according to three 
risk factors which were identified from multivariate analysis 
for APFFS, such as residual tumor size, decline in CA-125, and 
Table 1. Clinicopathologic characteristics (n=149)
Characteristic No. (%)
Age* (yr) 51 (18–77)
    ≤51 76 (51.0)
    >51 73 (49.0)
Histologic type
    Serous adenocarcinoma 125 (83.9)
    Endometrioid adenocarcinoma 6 (4.0)
    Clear cell carcinoma 11 (7.4)
    Mucinous adenocarcinoma 4 (2.7)
    Mixed/unclassified carcinoma 3 (2.0)
Histologic grade 
    1 14 (9.4)
    2 41 (27.5)
    3 73 (49.0)
    Unknown 21 (14.1)
Positive peritoneal cytology 95 (63.8)
Peritoneal metastasis (cm)
    ≤2 72 (48.3)
    >2 77 (51.7)
Lymph node involvement (pN1) 115 (54.8)
    Pelvic alone 48 (32.2)
    Pelvic and para-aortic 28 (18.8)
    Para-aortic alone 14 (9.4)
Residual disease (cm)
    None 8 (5.4)
    ≤2  98 (65.8)
    >2  32 (21.5)
    Unknown 11 (7.4)
Pretreatment CA-125* (U/mL) 604 (12.5-12,000)
    <35 12 (8.1)
    35-604 61 (40.9)
    ≥604 73 (49.0)
    Unknown 3 (2.0)
CA-125 decline (%)
    <90 56 (37.6)
    ≥90 81 (54.4)
    Unknown 12 (8.1)
*Median (range).
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lymph node involvement (Table 4). The steps of the clas-
sification process were as follows: In patients with no residual 
tumor size, even though it was difficult to compare because 
of the small numbers, lymph node (LN) negative patients did 
not fail regardless of decline in CA-125. However, LN positive 
patients demonstrated a 60% APF rate. In patients with a 
residual tumor size of less than 2 cm and a decline in CA-125 
over 90%, although 3 out of 22 LN negative patients (13.6%) 
failed regardless of decline in CA-125, LN positive patients 
demonstrated an APF rate of 30% (9/30). In patients with a 
Table 2. Univariate analysis of the prognostic factors (n=149)
Prognostic variable No.  of patients
5-yr APF-free survival
p-value
5-yr actuarial survival
p-value
% 95% CI % 95% CI
Age (yr) 0.03 <0.001
    <60 111 45.0 35.0-55.0 67.1 57.1-77.1
    ≥60 38 28.5 11.5-45.5 24.1 6.1-42.1
Histologic type 0.39 0.507
    Serous adenocarcinoma 125 40.6 28.6-52.6 55.4 45.4-65.4
    Other carcinomas 24 46.8 22.8-70.8 68.7 46.7-80.7
Grade 0.05 0.008
    1–2 55 50.7 36.7-69.7 69.1 55.1-83.1
    3 73 30.7 40.7-50.7 50.1 36.1-64.1
Peritoneal washing cytology <0.001 <0.001
    Negative 54 61.1 43.1-79.1 87.6 77.6-97.6
    Positive 95 24.1 15.9-32.3 39.5 27.5-51.5
Peritoneal metastasis (cm) <0.001 <0.001
    ≤2 72 59.0 47.0-71.0 72.7 65.7-84.7
    >2 77 21.0 9.0-33.0 38.7 24.7-52.7
Lymph node involvement (pN) 0.021 0.03
    Negative 59 54.6 40.6-68.6 66.2 52.2-80.2
    Positive 90 12.8 0-26.8 50.1 38.1-62.1
Residual disease (cm) < 0.001 0.001
    0-2 106 52.6 42.6-62.6 62.0 50.0-74.0
    >2 32 12.0 0.4-23.6 41.8 29.8-63.8
CA-125 decline (%) <0.001 <0.001
    <90 56 16.1 12.1-28.1 37.8 23.8-51.8
    ≥90 81 59.7 37.7-71.7 69.4 57.4-81.4
APF, abdominopelvic failure; CI, confidence interval.
Table 3. Multivariate analysis of the prognostic factors
Prognostic variable Subgroups
5-yr APF-free survival
p-value
5-yr actuarial survival
p-value
HR 95% CI HR 95% CI
Age (yr) ≥60 vs. <60 1.8 1.2-2.4 0.07 3.2 2.5-3.9 0.001
Grade 1-2 vs. 3 1.5 0.9-2.1 0.33 2.2 1.5-2.9 0.03
Peritoneal washing cytology Positive vs. negative 1.9 1.1-2.7 0.11 2.9 1.9-3.9 0.03
Peritoneal metastasis (cm) ≤2 vs. >2 1.3 0.7-1.9 0.40 1.5 0.7-2.3 0.31
Lymph nodes status Positive vs. negative 2.0 1.3-2.7 0.05 1.2 0.5-1.9 0.56
Residual disease (cm) >2 vs. 0-2 2.9 2.3-3.5 0.001 1.5 0.8-2.2 0.29
CA-125 decline (%) <90 vs. ≥90 3.5 2.9-4.1 <0.001 2.2 1.5-2.9 0.02
APF, abdominopelvic failure; CI, confidence interval; HR, hazard ratio.
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residual tumor size of less than 2 cm and a decline in CA-125 
of less than 90%, APF rates were much higher compared with 
the over 90% decline patients. In patients with residual tumor 
size larger than 2 cm, at least two thirds of the patients of all 
subgroups failed in the abdominopelvic spaces. Subgroups 
with a similar risk were gathered and their overall APF rate 
was calculated (Fig. 1). The intermediate and high risk groups 
comprised 55% and 43% of the overall patient population and 
their APF rates were 30% and 77%, respectively. The 5-year 
APFFS and OS according to risk subgroups are shown in Fig. 2. 
DISCUSSION
Our data demonstrated that APF was the predominant pat-
tern of treatment failure in EOC patients treated with definitive 
and adjuvant therapy, and failure sites were almost evenly 
distributed within the abdominopelvic cavity. While distant 
metastasis alone was observed in only four patients, more 
than a half of EOC patients experienced APF as the first failure 
within the first two years. Because APF eventually progresses 
to a fatal outcome in most patients, it is important to decide 
which consolidation therapy should be used to prevent APF. 
To decrease the incidence of APF, intraperitoneal chemo-
therapy and WART have been used and tested in clinical 
settings. Two recent meta-analyses provided supportive data 
for intraperitoneal chemotherapy with intravenous chemo-
therapy [6,7]. WART has also been considered to be one of the 
possible adjuvant therapies in EOC patients. The randomized 
trial by Sobre et al. [8] indicated that patients treated with 
consolidation WART had a significant better disease-free and 
overall survival in the subgroup with complete surgical and 
pathologic remission compared with patients treated with 
consolidation chemotherapy. Additionally, WART has some 
theoretical and practical advantages over other intraperitoneal 
approaches as follows: a more homogeneous dose distribu-
tion, better coverage of retroperitoneal lymph nodes, and the 
ability to treat all peritoneal surfaces without limitations from 
Table 4. Abdominopelvic failure in FIGO stage III epithelial ovarian 
cancer
Residual 
tumor size 
(cm)
CA-125 
decline (%)
Abdominopelvic failure rate (%)
LN– LN+
0 ≥90 0/2 (0) 3/5 (60)
0 <90 0/1 (0) NA
<2  ≥90 3/22 (13.6) 9/30 (30)
<2  <90 5/10 (50) 18/23 (78)
≥2  ≥90 2/2 (100) 8/12 (67)
≥2 <90 7/8 (88) 5/7 (71)
FIGO, International Federation of Gynecology and Obstetrics; LN, 
lymph node; NA, not available. 
Fig. 1. The definition of patient subgroups according to residual 
tumor size, decline in CA-125 and lymph node (LN) involvement.
Fig. 2. The 5-year abdominopelvic failure-free (A) and overall actuarial survival (B) rates according to risk group.
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the presence of postoperative adhesions [9]. 
However, many oncologists have been hesitant to use WART 
for several reasons. First, only a few trials have demonstrated 
any positive clinical benefits of WART for the management 
of EOC, although WART as an adjuvant treatment has been 
compared with chemotherapy in a small number of trials [5]. 
The combination of taxane and platinum, the current standard 
combination chemotherapy regimen, has shown superior 
therapeutic efficacy compared with previous chemotherapy 
regimens, and is generally acknowledged as the only adjuvant 
therapy. Second, the open-field technique has been conven-
tionally preferred to WART in gynecologic cancer patients. 
Acute and late treatment-related complications were found 
to be significant problems in some trials. At present, novel 
radiation oncological approaches consider the statification of 
patients with high risk clinicopathologic factors of APF, and 
more such approaches are being developed to deliver WART 
more safely and effectively.
Even though the implication of clinicopathologic factors may 
be different from one another, tumor stage, size of residual 
disease, histologic type and grade, surgical factors including 
tumor spillage, cytologically malignant ascites, and CA-125 
have been generally accepted as significant prognostic factors 
for EOC [10]. Until now, the prognostic classification of the 
Princess Margaret Hospital has been most frequently used to 
define the application of WART. Their multivariate analysis of 
prognostic factors showed stage, residuum and tumor grade 
and histological subtype were significantly independent 
predictors of relapse and survival. Based upon three variables, 
outcome was evaluated using a matrix to allow for the division 
of patients into two subgroups according to risk of relapse 
after WART [11]. The intermediate-risk subgroup comprised 
one third of all patients and showed a 5-year survival rate over 
70% when treated with WART that was significantly better 
compared with other treatment modalities. The high risk 
subgroup, 15% of total patient population, showed recurrence 
of 80% and survival rate of 30% at 5-year. The classification 
proved to be valid by subsequent studies [12,13] and has been 
adopted through several modifications in most studies [14]. 
However, this risk estimation might be different for current 
standard treatments, because the classification was founded 
on data from patients who had not undergone chemotherapy 
or been treated with platinum-based chemotherapy. Finally, 
new changes in treatment modalities should be considered 
for prognostic classifications, such as estimation of tumor 
bulkiness and response monitoring using CA-125, as well as 
the combination of taxane and platinum. 
In our study, patients were classified on the basis of this 
tumor burden category using three significant risk factors 
for APFFS as these seem to be primary consideration for 
consolidation WART. Because the low risk group had no APF 
in this study, no further consolidation treatment would be 
needed after primary surgery and adjuvant chemotherapy 
for these patients. High risk patients might be thought to not 
only have too large tumors of to be completely removed by 
surgery, but also to have aggressive biologic features which 
may lead to recurrence in a short period despite the use of 
current adjuvant therapy. For these patients, new approaches 
should be considered in view of biological aspects. Patients 
with intermediate risk may be considered to receive adjuvant 
WART. In our data, these population included patients with 
no residual size and positive LN regardless of status of decline 
of CA-125, patients with residual tumor less than 2 cm and 
negative LN irrespective of status of decline of CA-125 and 
patients with residual tumor less than 2 cm, positive LN and 
decline of CA-125 over than 90%. If disease-free status can be 
consolidated by WART as an adjuvant locoregional therapy, it 
can improve clinical outcomes and the quality of life of EOC 
patients. 
In addition to accurate identification of intermediate risk 
group based upon operative and pathologic findings, careful 
response evaluation after adjuvant chemotherapy is impor-
tant to decide further treatment policy. In the past, second-
look operation (SLO) was mainly performed to detect residual 
disease after primary treatment for EOC. However, even if 
stage III patients had negative in SLO, the recurrence substan-
tially developed up to 30% at 2 year and 50% at 5 year [15]. 
Moreover, Gynecologic Oncologic Group analysis showed SLO 
was not associated with longer survival of optimally resected 
stage III ovarian cancer in nonrandomized comparison [16]. 
Remarkable improvement of imaging technology has gradu-
ally replaced SLO. PET/CT before SLO showed high sensitivity 
from 78% to 93% when correlated with histologic findings 
after SLO [17,18]. Additionally, the combination of CA-125 and 
PET/CT has improved the identification of patients with recur-
rent disease [19]. Therefore, PET/CT is considered to be more 
suitable modality than SLO after adjuvant chemotherapy 
because of avoiding small bowel complication from additional 
operation.
One of the most challenging toxicities, in addition to small 
bowel toxicity, is to spare the hematopoietic function of bone 
marrow, because salvage chemotherapy plays a critical role 
in reducing tumor size and prolonging survival in recurrent 
EOC. Several investigators reported that helical tomotherapy 
is feasible and fast for WART with excellent coverage of the 
planning target size and effective sparing of bone marrow or-
gans at risk [20,21]. Recently, the Heidelberg group performed 
a phase I clinical trial to assess the feasibility and toxicity of 
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consolidative intensity-modulated WART (30 Gy/15 fractions) 
after surgery and chemotherapy in high-risk patients with 
advanced ovarian cancer. The treatment was well tolerated 
and late complications were manageable [22]. IMRT and 
helical tomotherapy make it technically possible to deliver 
high-dose radiation to a risky area for better tumor control 
without raising WART dose using a simultaneous integrated 
boost technique. However, the caution is needed in the use 
of those techniques because of uncertainties in radiation dose 
delivery induced by intrafraction abdominal organ motion. To 
minimize those uncertainties, a planning four-dimensional CT 
scan with/without patient immobilization is recommended. 
In conclusions, our data showed that APF is the dominant 
pattern of failures in EOC patients. Size of residual disease, LN 
involvement and decline in CA-125 were significantly prog-
nostic factors of APF after primary treatment. Even though 
more analyses are needed to validate this stratification, WART 
using the IMRT technique may be considered to reduce APF 
in FIGO stage III EOC patients with intermediate risk. Further 
analyses are needed to define the subgroup for which WART 
can be applied as a consolidation for EOC patients.
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